SCHEMBL4977891

SCHEMBL4977891

CC12CCC(O)C(C)(C)C1Cc1c(O)ccc(C(=O)/C=C/c3ccc(O)cc3)c1O2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 5/20 0.43
▸ CHRNA7 P36544 2/20 0.43
▸ CYP3A4 P08684 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ HPGD P15428 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ TDP1 Q9NUW8 3/20 0.40
▸ ALOX15 P16050 3/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ BACE1 P56817 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ GMNN O75496 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ MMP1 P03956 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977898 1.00 OSBP (0.43) OSBPCHRNA7CYP3A4MEN1MAPT
SCHEMBL14201287 0.93 MAOB (0.43) OSBPMAPTKMT2AMAPK1ALDH1A1
SCHEMBL14523859 0.83 PTPN1 (0.47) CHRNA7CYP3A4MEN1MAPTHPGD
SCHEMBL4982221 0.76 PTPN1 (0.51) CHRNA7CYP3A4MEN1MAPTHPGD
SCHEMBL5519370 0.76 PTPN1 (0.51) CHRNA7CYP3A4MEN1MAPTHPGD
SCHEMBL15620334 0.76 NFKB1 (0.48) CHRNA7CYP3A4MEN1MAPTHPGD
SCHEMBL15620335 0.72 NFKB1 (0.48) CHRNA7CYP3A4MEN1MAPTHPGD
SCHEMBL14523845 0.71 MAOB (0.52) CYP3A4MEN1MAPTHPGDKMT2A
SCHEMBL5997891 0.71 MAOB (0.52) CYP3A4MEN1MAPTHPGDKMT2A
SCHEMBL14518094 0.70 MAOB (0.45) MEN1MAPTKMT2AMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 — — EP claimed
US-7361774-B2 Chalcone compound TAKARA BIO INC. (JP) 2008-04-22 — — US disclosed
US-20080008773-A1 Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species OHNOGI HIROMU 2008-01-10 — — US disclosed
US-20080008773-A1 Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species OHNOGI HIROMU 2008-01-10 — — US disclosed
US-20080008773-A1 Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species OHNOGI HIROMU 2008-01-10 — — US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092587-A1 Extract from plant of japanese parsley family and process for producing the same TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092587-A1 Extract from plant of japanese parsley family and process for producing the same TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20060039998-A1 Remedies TAKARA BIO INC. (JP) 2006-02-23 — — US disclosed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 — — EP disclosed
US-20050272809-A1 Remedies TAKARA BIO INC. (JP) 2005-12-08 — — US disclosed
EP-1574506-A1 REMEDIES TAKARA BIO INC. (JP) 2005-09-14 — — EP disclosed
EP-1563841-A1 REMEDIES TAKARA BIO INC. (JP) 2005-08-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092587-A1 Extract from plant of japanese parsley family and process for producing the same ALDOA, FABP4, UGDH OSBP 453/4885CHRNA7 4448/4885CYP3A4 3636/4885
US-20080008773-A1 Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species BMP2, BMP1, BMP4 OSBP 309/4885CHRNA7 4816/4885CYP3A4 4790/4885
US-20050272809-A1 Remedies NOS2, AKR1C3, CBR1 OSBP 438/4885CHRNA7 734/4885CYP3A4 2724/4885
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP OSBP 486/4885CHRNA7 4487/4885CYP3A4 3641/4885
US-20060039998-A1 Remedies BMP2, BMP1, BMP6 OSBP 201/4885CHRNA7 4571/4885CYP3A4 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback